Meeting
2021 ASCO Annual Meeting
Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy.
Presenter
Jessica Cecile Hassel, MD
Department of Dermatology and National Center for Tumor Diseases (NCT), Heidelberg University Hospital
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03278665
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9545)
DOI
10.1200/JCO.2021.39.15_suppl.9545
Abstract #
9545
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2021 Gastrointestinal Cancers Symposium
Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Speaker: Jeffrey Sum Lung Wong
Videos & Slides
2017 ASCO Annual Meeting
Phase 1/2 KEYNOTE-051 study of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1+ advanced, relapsed, or refractory solid tumor or lymphoma.
Speaker: Birgit Geoerger, MD
Videos & Slides
2024 ASCO Annual Meeting
A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.
Speaker: Eric Christenson, MD
Videos & Slides
2024 ASCO Annual Meeting
International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI).
Speaker: Anthony B. El-Khoueiry, MD